Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | STIM1 | Q13586 | 2/20 | 0.49 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1594289 | 0.87 | RAB9A (0.73) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5211996 | 0.86 | HDAC3 (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL3249785 | 0.83 | HDAC3 (0.77) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Dimethylamine SCHEMBL18241027 | 0.83 | RAB9A (0.53) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5623695 | 0.81 | HDAC3 (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5210893 | 0.80 | HDAC3 (0.55) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5212779 | 0.79 | ALDH1A1 (0.53) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1593790 | 0.78 | RAB9A (0.73) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1593777 | 0.75 | RAB9A (0.73) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1594460 | 0.75 | RAB9A (0.66) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285554-B2 | Pyrazolyl-substituted benzene or thiophene coupled to an aryl, cycloalkyl or heteroaryl ring by an amide, e.g., 4'-chloro-5-(1,4-dimethyl-5-trifluoromethyl-1H-pyrazol-3-yl)thiophene-2-carboxyanilide; calcium release-activated calcium channel inhibitors; treating bronchial asthma and rheumatoid arthritis | ASTELLAS PHARMA INC. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-7285554-B2 | Pyrazolyl-substituted benzene or thiophene coupled to an aryl, cycloalkyl or heteroaryl ring by an amide, e.g., 4'-chloro-5-(1,4-dimethyl-5-trifluoromethyl-1H-pyrazol-3-yl)thiophene-2-carboxyanilide; calcium release-activated calcium channel inhibitors; treating bronchial asthma and rheumatoid arthritis | ASTELLAS PHARMA INC. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-7285554-B2 | Pyrazolyl-substituted benzene or thiophene coupled to an aryl, cycloalkyl or heteroaryl ring by an amide, e.g., 4'-chloro-5-(1,4-dimethyl-5-trifluoromethyl-1H-pyrazol-3-yl)thiophene-2-carboxyanilide; calcium release-activated calcium channel inhibitors; treating bronchial asthma and rheumatoid arthritis | ASTELLAS PHARMA INC. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-7247635-B2 | Pyrazole derivative | ASTELLAS PHARMA INC. (JP) | 2007-07-24 | — | — | US | disclosed |
| US-7247635-B2 | Pyrazole derivative | ASTELLAS PHARMA INC. (JP) | 2007-07-24 | — | — | US | disclosed |
| US-7247635-B2 | Pyrazole derivative | ASTELLAS PHARMA INC. (JP) | 2007-07-24 | — | — | US | disclosed |
| EP-1024138-B1 | PYRAZOLE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2007-04-25 | — | — | EP | disclosed |
| US-20060264430-A1 | Pyrazolyl-substituted benzene or thiophene coupled to an aryl, cycloalkyl or heteroaryl ring by an amide, e.g., 4'-chloro-5-(1,4-dimethyl-5-trifluoromethyl-1H-pyrazol-3-yl)thiophene-2-carboxyanilide; calcium release-activated calcium channel inhibitors; treating bronchial asthma and rheumatoid arthritis | ASTELLAS PHARMA INC. | 2006-11-23 | — | — | US | disclosed |
| US-6958339-B2 | Pyrazole derivative | ASTELLAS PHARMA INC. (JP) | 2005-10-25 | — | — | US | disclosed |
| US-20050234055-A1 | Pyrazole derivative | ASTELLAS PHARMA INC. | 2005-10-20 | — | — | US | disclosed |
| US-6348480-B1 | CALCIUM CHANNEL BLOCKERS AND ANTIINFLAMMATORY AGENTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| US-20010011090-A1 | Pyrazole derivative | ASTELLAS PHARMA INC. (JP) | 2001-08-02 | — | — | US | disclosed |
| EP-1024138-A1 | PYRAZOLE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2000-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234055-A1 | Pyrazole derivative | RYR2, RYR1, NR1I3 | HDAC3 302/4885HDAC4 990/4885HDAC1 752/4885 |
| US-20060264430-A1 | Pyrazolyl-substituted benzene or thiophene coupled to an aryl, cycloalkyl or heteroaryl ring by an amide, e.g., 4'-chloro-5-(1,4-dimethyl-5-trifluoromethyl-1H-pyrazol-3-yl)thiophene-2-carboxyanilide; calcium release-activated calcium channel inhibitors; treating bronchial asthma and rheumatoid arthritis | RYR2, HRH4, RYR1 | HDAC3 188/4885HDAC4 739/4885HDAC1 489/4885 |
| US-20010011090-A1 | Pyrazole derivative | RYR1, CACNA1E, RYR2 | HDAC3 663/4885HDAC4 2208/4885HDAC1 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.